Oncologic has developed a proprietary anti-cancer technology anticipated to give CURE rates of approximately 90% for a majority of metastasized solid tumors, including malignancies of the breast, lung and colon. By contrast, current chemotherapy methods that may greatly reduce the mass of metastasized cancer are seldom CURES: the cancer reappears in an untreatable form, resistant to chemotherapy. The approach is called S.T.A.R.™ which stands for Selectively Targeted Amplified Radiotherapy. The center of the S.T.A.R.™ advantage is a powerful nanotechnology that unites advances in molecular biology, proteomics, and chemotherapeutics into a radically different intravenous therapy sequence that “burns out” primary and metastatic tumors by the delivery and immobilization of radioisotopes, without significant damage to normal cells and tissues.
Clovis Oncology: Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in… See Company Profile »